Concepts (312)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitamin D | 20 | 2024 | 73 | 4.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2024 | 664 | 3.940 |
Why?
|
| Prediabetic State | 8 | 2024 | 52 | 3.580 |
Why?
|
| Postmenopause | 26 | 2025 | 248 | 2.930 |
Why?
|
| Weight Loss | 8 | 2025 | 294 | 2.020 |
Why?
|
| Women's Health | 20 | 2023 | 197 | 1.780 |
Why?
|
| Humans | 98 | 2025 | 17314 | 1.730 |
Why?
|
| Female | 83 | 2025 | 12396 | 1.630 |
Why?
|
| Cholecalciferol | 10 | 2019 | 16 | 1.610 |
Why?
|
| Obesity | 13 | 2025 | 814 | 1.590 |
Why?
|
| Aged | 63 | 2025 | 6084 | 1.540 |
Why?
|
| Dietary Supplements | 15 | 2024 | 85 | 1.420 |
Why?
|
| Accidental Falls | 4 | 2015 | 46 | 1.400 |
Why?
|
| Hypoglycemic Agents | 4 | 2024 | 250 | 1.360 |
Why?
|
| Menopause | 6 | 2020 | 68 | 1.340 |
Why?
|
| Blood Glucose | 6 | 2024 | 314 | 1.290 |
Why?
|
| Fractures, Bone | 7 | 2022 | 92 | 1.280 |
Why?
|
| Risk Factors | 43 | 2025 | 3258 | 1.280 |
Why?
|
| Vitamins | 7 | 2024 | 60 | 1.240 |
Why?
|
| Cognition | 7 | 2024 | 81 | 1.210 |
Why?
|
| Mass Screening | 4 | 2022 | 672 | 1.180 |
Why?
|
| Osteoporotic Fractures | 7 | 2024 | 40 | 1.160 |
Why?
|
| Vitamin D Deficiency | 4 | 2015 | 21 | 1.130 |
Why?
|
| Middle Aged | 51 | 2025 | 7836 | 1.110 |
Why?
|
| Calcium Carbonate | 6 | 2019 | 9 | 1.070 |
Why?
|
| Prenatal Care | 2 | 2020 | 127 | 1.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2024 | 34 | 1.040 |
Why?
|
| Prospective Studies | 26 | 2025 | 1226 | 1.020 |
Why?
|
| Behavior Therapy | 4 | 2021 | 126 | 0.940 |
Why?
|
| Exercise Therapy | 3 | 2015 | 72 | 0.930 |
Why?
|
| Calcium, Dietary | 5 | 2017 | 28 | 0.920 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 532 | 0.910 |
Why?
|
| Metformin | 2 | 2022 | 50 | 0.870 |
Why?
|
| Estrogen Replacement Therapy | 7 | 2017 | 100 | 0.870 |
Why?
|
| Aging | 4 | 2015 | 160 | 0.810 |
Why?
|
| Body Mass Index | 18 | 2025 | 937 | 0.810 |
Why?
|
| Cognitive Dysfunction | 3 | 2024 | 53 | 0.810 |
Why?
|
| Hip Fractures | 6 | 2016 | 71 | 0.790 |
Why?
|
| Testosterone | 3 | 2014 | 22 | 0.790 |
Why?
|
| Estradiol | 4 | 2014 | 23 | 0.780 |
Why?
|
| Calcium | 6 | 2020 | 30 | 0.770 |
Why?
|
| Hot Flashes | 6 | 2020 | 38 | 0.760 |
Why?
|
| Estrogens | 5 | 2022 | 60 | 0.750 |
Why?
|
| Health Behavior | 6 | 2021 | 346 | 0.740 |
Why?
|
| Glycated Hemoglobin A | 3 | 2020 | 184 | 0.730 |
Why?
|
| Dementia | 3 | 2020 | 121 | 0.730 |
Why?
|
| Weight Gain | 6 | 2020 | 156 | 0.710 |
Why?
|
| Aged, 80 and over | 18 | 2024 | 1925 | 0.710 |
Why?
|
| Anti-Obesity Agents | 2 | 2018 | 18 | 0.680 |
Why?
|
| Male | 20 | 2024 | 9804 | 0.660 |
Why?
|
| Diet | 5 | 2024 | 355 | 0.650 |
Why?
|
| Sex Hormone-Binding Globulin | 5 | 2016 | 21 | 0.630 |
Why?
|
| Incidence | 14 | 2019 | 1266 | 0.630 |
Why?
|
| Adult | 20 | 2024 | 7500 | 0.620 |
Why?
|
| United States | 24 | 2025 | 3866 | 0.610 |
Why?
|
| Preconception Care | 2 | 2016 | 40 | 0.610 |
Why?
|
| Breast Density | 4 | 2022 | 31 | 0.600 |
Why?
|
| Cohort Studies | 17 | 2024 | 2514 | 0.600 |
Why?
|
| Obesity Management | 1 | 2018 | 4 | 0.590 |
Why?
|
| Pregnancy Complications | 2 | 2021 | 197 | 0.570 |
Why?
|
| Primary Health Care | 2 | 2015 | 726 | 0.560 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2016 | 27 | 0.550 |
Why?
|
| Follow-Up Studies | 15 | 2023 | 1151 | 0.540 |
Why?
|
| Demography | 1 | 2017 | 93 | 0.540 |
Why?
|
| Femoral Fractures | 1 | 2017 | 23 | 0.530 |
Why?
|
| Menstruation | 1 | 2017 | 7 | 0.530 |
Why?
|
| Sleep | 3 | 2024 | 57 | 0.530 |
Why?
|
| Reproductive History | 1 | 2017 | 17 | 0.520 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 54 | 0.520 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 1280 | 0.510 |
Why?
|
| Waist Circumference | 3 | 2025 | 33 | 0.510 |
Why?
|
| Overweight | 6 | 2025 | 266 | 0.500 |
Why?
|
| Breast | 4 | 2019 | 84 | 0.490 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 49 | 0.480 |
Why?
|
| Residence Characteristics | 2 | 2017 | 253 | 0.480 |
Why?
|
| Treatment Outcome | 10 | 2021 | 1160 | 0.480 |
Why?
|
| Pregnancy | 8 | 2024 | 1463 | 0.480 |
Why?
|
| Double-Blind Method | 10 | 2019 | 142 | 0.460 |
Why?
|
| Time Factors | 9 | 2019 | 1039 | 0.450 |
Why?
|
| Body Composition | 3 | 2023 | 91 | 0.430 |
Why?
|
| Diphosphonates | 1 | 2014 | 63 | 0.420 |
Why?
|
| Macular Degeneration | 4 | 2015 | 20 | 0.410 |
Why?
|
| Bone Density | 6 | 2019 | 94 | 0.410 |
Why?
|
| Proportional Hazards Models | 12 | 2019 | 701 | 0.410 |
Why?
|
| Nonprescription Drugs | 1 | 2013 | 6 | 0.410 |
Why?
|
| Drug Compounding | 1 | 2013 | 5 | 0.410 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 969 | 0.400 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2023 | 312 | 0.390 |
Why?
|
| Neoplasms | 5 | 2019 | 446 | 0.370 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 363 | 0.340 |
Why?
|
| Surveys and Questionnaires | 8 | 2019 | 1282 | 0.340 |
Why?
|
| Spinal Fractures | 3 | 2016 | 12 | 0.330 |
Why?
|
| Mortality | 2 | 2025 | 116 | 0.330 |
Why?
|
| Health Status Disparities | 1 | 2011 | 149 | 0.320 |
Why?
|
| Adolescent | 8 | 2022 | 3538 | 0.320 |
Why?
|
| Osteoporosis, Postmenopausal | 4 | 2019 | 42 | 0.310 |
Why?
|
| Preventive Health Services | 2 | 2022 | 147 | 0.300 |
Why?
|
| Body Weight | 3 | 2020 | 203 | 0.300 |
Why?
|
| Menarche | 2 | 2019 | 28 | 0.290 |
Why?
|
| Risk Assessment | 6 | 2025 | 1076 | 0.280 |
Why?
|
| Age Factors | 6 | 2019 | 878 | 0.280 |
Why?
|
| Sweating | 3 | 2017 | 8 | 0.270 |
Why?
|
| Child | 7 | 2023 | 2403 | 0.270 |
Why?
|
| Exercise | 3 | 2021 | 515 | 0.260 |
Why?
|
| Life Style | 3 | 2015 | 316 | 0.260 |
Why?
|
| Fetal Macrosomia | 3 | 2021 | 27 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 102 | 0.240 |
Why?
|
| Adiposity | 2 | 2023 | 67 | 0.240 |
Why?
|
| Self Report | 5 | 2019 | 257 | 0.240 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 114 | 0.230 |
Why?
|
| Emotions | 2 | 2015 | 34 | 0.230 |
Why?
|
| Fatigue | 2 | 2015 | 32 | 0.230 |
Why?
|
| Sex Factors | 2 | 2024 | 603 | 0.230 |
Why?
|
| Sleep Wake Disorders | 2 | 2015 | 34 | 0.220 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2024 | 37 | 0.220 |
Why?
|
| Sex Characteristics | 1 | 2024 | 66 | 0.220 |
Why?
|
| Diet, Reducing | 3 | 2015 | 22 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2017 | 2415 | 0.220 |
Why?
|
| Neuropsychological Tests | 3 | 2016 | 43 | 0.220 |
Why?
|
| Insulin Resistance | 1 | 2024 | 128 | 0.220 |
Why?
|
| Patient Compliance | 2 | 2016 | 277 | 0.210 |
Why?
|
| Carotenoids | 2 | 2014 | 28 | 0.210 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 193 | 0.200 |
Why?
|
| Body Size | 2 | 2020 | 31 | 0.200 |
Why?
|
| Young Adult | 5 | 2022 | 2465 | 0.190 |
Why?
|
| Osteoporosis | 2 | 2014 | 74 | 0.190 |
Why?
|
| Feeding Behavior | 3 | 2024 | 163 | 0.190 |
Why?
|
| Premature Birth | 1 | 2023 | 132 | 0.180 |
Why?
|
| Advisory Committees | 1 | 2022 | 112 | 0.180 |
Why?
|
| Odds Ratio | 8 | 2017 | 640 | 0.180 |
Why?
|
| Geriatric Assessment | 2 | 2012 | 43 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 452 | 0.170 |
Why?
|
| Pregnancy Trimesters | 1 | 2020 | 29 | 0.170 |
Why?
|
| Glycemic Load | 1 | 2020 | 1 | 0.160 |
Why?
|
| Glycemic Index | 1 | 2020 | 19 | 0.160 |
Why?
|
| Sexual Maturation | 1 | 2019 | 8 | 0.160 |
Why?
|
| Anthropometry | 1 | 2020 | 60 | 0.160 |
Why?
|
| Adipose Tissue | 2 | 2018 | 65 | 0.160 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 99 | 0.160 |
Why?
|
| Hispanic Americans | 3 | 2021 | 375 | 0.160 |
Why?
|
| Contraceptives, Oral | 1 | 1999 | 25 | 0.160 |
Why?
|
| Counseling | 1 | 2021 | 174 | 0.160 |
Why?
|
| Parity | 1 | 2019 | 57 | 0.160 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 158 | 0.150 |
Why?
|
| Cholesterol, LDL | 2 | 2017 | 112 | 0.150 |
Why?
|
| Puberty | 1 | 2019 | 58 | 0.150 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 605 | 0.150 |
Why?
|
| Logistic Models | 3 | 2016 | 879 | 0.150 |
Why?
|
| Dietary Fats | 2 | 2016 | 89 | 0.150 |
Why?
|
| Bias | 1 | 2018 | 96 | 0.140 |
Why?
|
| Breast Feeding | 1 | 2019 | 113 | 0.140 |
Why?
|
| European Continental Ancestry Group | 3 | 2017 | 476 | 0.140 |
Why?
|
| Health Promotion | 1 | 2021 | 279 | 0.140 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2017 | 15 | 0.140 |
Why?
|
| Ovariectomy | 1 | 2017 | 9 | 0.140 |
Why?
|
| Receptors, Neurokinin-3 | 1 | 2017 | 1 | 0.130 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 13 | 0.130 |
Why?
|
| Hysterectomy | 1 | 2017 | 29 | 0.130 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 43 | 0.130 |
Why?
|
| Biomarkers | 2 | 2015 | 307 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 37 | 0.130 |
Why?
|
| Calcifediol | 2 | 2014 | 2 | 0.130 |
Why?
|
| Body Height | 2 | 2018 | 60 | 0.130 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2016 | 2 | 0.130 |
Why?
|
| Diet, Mediterranean | 1 | 2016 | 7 | 0.130 |
Why?
|
| Reproduction | 1 | 2016 | 12 | 0.130 |
Why?
|
| Pregnancy Rate | 1 | 2016 | 6 | 0.130 |
Why?
|
| Cause of Death | 2 | 2019 | 176 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2015 | 8 | 0.120 |
Why?
|
| Complement Factor I | 1 | 2015 | 1 | 0.120 |
Why?
|
| Age of Onset | 1 | 2015 | 70 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 112 | 0.120 |
Why?
|
| Institutionalization | 1 | 2015 | 1 | 0.120 |
Why?
|
| African Americans | 2 | 2017 | 439 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 145 | 0.120 |
Why?
|
| Homes for the Aged | 1 | 2015 | 6 | 0.120 |
Why?
|
| Vasomotor System | 1 | 2014 | 4 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2020 | 704 | 0.120 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 26 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 674 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 7 | 0.110 |
Why?
|
| Insulin | 1 | 2015 | 188 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 69 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 44 | 0.110 |
Why?
|
| Risk | 2 | 2009 | 496 | 0.110 |
Why?
|
| Oregon | 1 | 2014 | 170 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2015 | 147 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 62 | 0.110 |
Why?
|
| Hand Strength | 1 | 2013 | 10 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 165 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 171 | 0.100 |
Why?
|
| Memory | 1 | 2013 | 12 | 0.100 |
Why?
|
| Washington | 1 | 2014 | 384 | 0.100 |
Why?
|
| Cognition Disorders | 2 | 2012 | 30 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 184 | 0.100 |
Why?
|
| Retinal Pigments | 1 | 2013 | 3 | 0.100 |
Why?
|
| Asian Americans | 1 | 2014 | 163 | 0.100 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2012 | 2 | 0.100 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2012 | 4 | 0.100 |
Why?
|
| Walking | 1 | 2013 | 89 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 123 | 0.100 |
Why?
|
| Research Design | 2 | 2011 | 336 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 390 | 0.100 |
Why?
|
| Thyroid Diseases | 1 | 2012 | 2 | 0.090 |
Why?
|
| Thyroxine | 1 | 2012 | 7 | 0.090 |
Why?
|
| Thyroid Gland | 1 | 2012 | 6 | 0.090 |
Why?
|
| Infant, Newborn | 3 | 2023 | 805 | 0.090 |
Why?
|
| Thyrotropin | 1 | 2012 | 7 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2014 | 235 | 0.090 |
Why?
|
| Lactones | 1 | 2011 | 11 | 0.090 |
Why?
|
| Diabetes, Gestational | 2 | 2021 | 311 | 0.090 |
Why?
|
| Early Medical Intervention | 1 | 2011 | 10 | 0.090 |
Why?
|
| Prevalence | 4 | 2016 | 840 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2011 | 20 | 0.090 |
Why?
|
| World Health Organization | 1 | 2011 | 10 | 0.090 |
Why?
|
| Models, Biological | 1 | 2011 | 28 | 0.090 |
Why?
|
| Absorptiometry, Photon | 2 | 2023 | 51 | 0.090 |
Why?
|
| Melanoma | 1 | 2011 | 35 | 0.090 |
Why?
|
| Survival Rate | 1 | 2011 | 252 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 87 | 0.090 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 142 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 58 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 169 | 0.080 |
Why?
|
| Mammography | 2 | 2022 | 168 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 107 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2020 | 82 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2017 | 1098 | 0.070 |
Why?
|
| Depression | 1 | 2012 | 486 | 0.070 |
Why?
|
| Sleep Deprivation | 1 | 2007 | 3 | 0.070 |
Why?
|
| Stroke | 2 | 2019 | 309 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 149 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 622 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 437 | 0.060 |
Why?
|
| Genotype | 2 | 2015 | 223 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 535 | 0.060 |
Why?
|
| Prognosis | 2 | 2011 | 603 | 0.050 |
Why?
|
| Maternal Age | 1 | 2021 | 74 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2021 | 33 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2001 | 72 | 0.040 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 39 | 0.040 |
Why?
|
| Community Health Centers | 1 | 2021 | 64 | 0.040 |
Why?
|
| Dementia, Vascular | 1 | 2020 | 4 | 0.040 |
Why?
|
| Fasting | 1 | 2020 | 46 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 107 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2020 | 59 | 0.040 |
Why?
|
| Thinness | 1 | 2020 | 31 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 21 | 0.040 |
Why?
|
| Hip Joint | 1 | 2019 | 3 | 0.040 |
Why?
|
| Femur Neck | 1 | 2019 | 5 | 0.040 |
Why?
|
| Actigraphy | 1 | 2019 | 14 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 31 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 55 | 0.040 |
Why?
|
| Biopsy | 1 | 1999 | 82 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 81 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 71 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 1999 | 338 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 1999 | 224 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 6 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 6 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 8 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 3 | 0.030 |
Why?
|
| Protective Factors | 1 | 2017 | 32 | 0.030 |
Why?
|
| Intention | 1 | 2017 | 30 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 54 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 52 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 14 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 24 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 45 | 0.030 |
Why?
|
| Complement Factor B | 1 | 2015 | 1 | 0.030 |
Why?
|
| Complement C3 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Complement Factor H | 1 | 2015 | 2 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 248 | 0.030 |
Why?
|
| Proteins | 1 | 2015 | 15 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 26 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2015 | 6 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 2 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 153 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 30 | 0.030 |
Why?
|
| Cholesterol | 1 | 2014 | 82 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 69 | 0.030 |
Why?
|
| Fetal Development | 1 | 2014 | 14 | 0.030 |
Why?
|
| beta-Carotene 15,15'-Monooxygenase | 1 | 2013 | 1 | 0.030 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2013 | 1 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2015 | 275 | 0.030 |
Why?
|
| Urinary Calculi | 1 | 2012 | 1 | 0.030 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2012 | 2 | 0.030 |
Why?
|
| Sunlight | 1 | 2012 | 13 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 560 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 33 | 0.020 |
Why?
|
| Edible Grain | 1 | 2012 | 14 | 0.020 |
Why?
|
| Fruit | 1 | 2012 | 80 | 0.020 |
Why?
|
| Seasons | 1 | 2012 | 113 | 0.020 |
Why?
|
| Vegetables | 1 | 2012 | 88 | 0.020 |
Why?
|
| Thyroid Function Tests | 1 | 2012 | 2 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2015 | 451 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2011 | 10 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 16 | 0.020 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2011 | 84 | 0.020 |
Why?
|
| Zeaxanthins | 1 | 2010 | 5 | 0.020 |
Why?
|
| Tocopherols | 1 | 2010 | 5 | 0.020 |
Why?
|
| Xanthophylls | 1 | 2010 | 6 | 0.020 |
Why?
|
| Lutein | 1 | 2010 | 7 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 10 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 58 | 0.020 |
Why?
|
| Motor Activity | 1 | 2012 | 208 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2012 | 286 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 1 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 280 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 170 | 0.020 |
Why?
|
Concepts
(312)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(8)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->